Business Context and Reporting Period
Company: Jasper Therapeutics, Inc. (JSPR)
Filing Type: Form 8-K (Current Report)
Date: July 16, 2026
Event: Completion of the acquisition of Kira Pharmaceuticals ("Kira") via a Merger Agreement and concurrent private placement financing.
Key Financial Metrics and Transaction Details
- Acquisition Consideration: Issuance of 5,195,009 shares of Common Stock and 4,644,977 shares of Non-Voting Convertible Preferred Stock (convertible at 61:1 ratio) to Kira shareholders.
- Financing (PIPE): Sale of approximately 4.7 million shares of Preferred Stock for an aggregate cash purchase price of approximately $132 million.
- Licensing Revenue: Kira entered a license agreement with Mirador Therapeutics on July 13, 2026, securing a $12 million upfront payment.
- Contingent Value Rights (CVR): Pre-merger Jasper shareholders received CVRs entitling them to a pro-rata share of a $30 million milestone payment if a Priority Review Voucher is issued for briquilimab by December 31, 2028.
- Post-Transaction Ownership (Fully Diluted):
- Pre-transaction Jasper equityholders: ~6.68%
- Former Kira equityholders: ~49.86%
- PIPE Investors: ~43.46%
Material Changes Versus Prior Period
This filing represents a transformative change in the company's capital structure and asset base rather than a standard periodic financial update. Key changes include:
- Asset Acquisition: Jasper acquired Kira's assets, including proprietary anti-C5a antibody (KP301) and small molecule (KP402) programs.
- Capital Structure: Significant dilution of pre-transaction Jasper shareholders, who now hold a minority stake (~6.68%) following the merger and PIPE financing.
- Liquidity: The company secured approximately $132 million in cash proceeds from the PIPE financing, pending closing on July 20, 2026.
- Management: Resignation of two directors (Vishal Kapoor, Scott Brun) and appointment of Patrick Crutcher (Director) and Matthew Ros (COO).
Guidance, Outlook, and Risks
- Regulatory Milestones: The CVR agreement hinges on the FDA issuing a Priority Review Voucher for briquilimab by December 31, 2028.
- Stockholder Approval: The company must hold a stockholder meeting within 120 days to approve the conversion of Preferred Stock to Common Stock and ratify the new director appointment.
- Lock-Up Agreements: Directors, officers, and certain stockholders of both Jasper and Kira are subject to an 180-day lock-up period on share sales.
- Risks: Risks include the failure to consummate the Financing, inability to obtain stockholder approval for Preferred Stock conversion, and the uncertainty of achieving the CVR milestone. The filing explicitly states that financial statements for the acquired business and pro forma information are not yet included and will be filed within 71 days.
Investor Verification Checklist
- Verify the closing of the $132 million PIPE financing scheduled for July 20, 2026.
- Monitor the filing of the proxy statement for the stockholder meeting required to approve the conversion of Preferred Stock.
- Review the upcoming amendment to the 8-K (due within 71 days) for Kira's financial statements and pro forma combined financial information.
- Confirm the status of the Mirador Therapeutics license agreement and the receipt of the $12 million upfront payment.
- Track the development progress of briquilimab to assess the likelihood of the $30 million CVR milestone payment.